Ben Davidson
- Associate Professor and Senior Consultant; MD PhD
- +47 900 34 019
Present position: Senior Pathologist, Department of Pathology, Norwegian Radium Hospital, Oslo University Hospital; Professor, Faculty of Medicine, University of Oslo
Education and brief chronology of employment
2004-present: Staff pathologist, Department of Pathology, Norwegian Radium Hospital, Oslo, Norway; Sub-specialist in cytopathology and gynecologic pathology
2003-2004: Post-doctoral fellow at NCI/NIH, Bethesda MD
1998-2001: Resident (combined with PhD program), Department of Pathology, Norwegian Radium Hospital, Oslo, Norway
1994-1998: Resident, Department of Pathology, Sheba Medical Center, Tel Hashomer, Israel
1986-1992: Medical studies in Sackler School of Medicine, Tel-Aviv University, Israel
Membership in professional and scientific societies
- The American Association for Cancer Research
- The International Academy of Pathology (Norwegian division)
- The European Society of Pathology
- The International Society of Gynecological Pathology
- Nordic Society of Gynecologic Oncology
- International Academy of Cytology (Norwegian division)
Scientific appointments
2016-: Associate Editor, Pleura and Peritoneum
2016-: Editorial board member in Acta Cytologica
2012-: Editorial board member in Gynecologic Oncology
2011-: Editorial board member in Human Pathology
2010-: Editorial board member in Virchows Archiv
2017-2018: Senior Editor, International Journal of Gynecological Cancer
2011--2016: Associate Editor, Frontiers in Women’s Cancer
2009-2016: Board member and research adviser to the European Society of Cytological Societies (EFCS)
2005-2012: Section Editor in Diagnostic Cytopathology
Invited speaker: 44 sessions in international conferences in 2004-2019
Publications (excluding abstracts) in peer-reviewed journals: 340 articles per October 2019.
Editor of a book on serous effusions with Springer.
Author of 8 chapters in other books.
Download CV (in Word format)
Publications 2024
Expression of PRAME in high-grade serous carcinoma is associated with higher residual disease volume and Occludin expression
Pathol Res Pract, 266, 155787 (in press)
DOI 10.1016/j.prp.2024.155787, PubMed 39709875
Efficient CAR T cell targeting of the CA125 extracellular repeat domain of MUC16
J Immunother Cancer, 12 (4)
DOI 10.1136/jitc-2023-008179, PubMed 38604812
Comprehensive molecular characterization of early stage grade 3 endometrioid endometrial adenocarcinoma
Gynecol Oncol, 189, 138-145
DOI 10.1016/j.ygyno.2024.07.677, PubMed 39126895
Oncologic outcomes based on lymphovascular space invasion in node-negative FIGO 2009 stage I endometrioid endometrial adenocarcinoma: a multicenter retrospective cohort study
Int J Gynecol Cancer, 34 (10), 1485-1492
DOI 10.1136/ijgc-2024-005746, PubMed 39074932
Correction to: Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
Virchows Arch, 484 (5), 875
DOI 10.1007/s00428-023-03567-w, PubMed 37261507
Different Frequency and Clinical Role for MTAP Loss in Pleural and Peritoneal Mesothelioma
Appl Immunohistochem Mol Morphol, 32 (6), 280-284
DOI 10.1097/PAI.0000000000001206, PubMed 38812360
Molecular characteristics of tubo-ovarian carcinosarcoma at different anatomic locations
Virchows Arch, 485 (6), 1053-1061
DOI 10.1007/s00428-024-03821-9, PubMed 38733380
Stathmin is an Independent Prognostic Marker of Poor Outcome in Uterine Leiomyosarcoma
Int J Gynecol Pathol, 44 (1), 56-66
DOI 10.1097/PGP.0000000000001030, PubMed 38847524
Endometrial carcinomas with ambiguous histology often harbor TP53 mutations
Virchows Arch (in press)
DOI 10.1007/s00428-024-03912-7, PubMed 39235515
ESGO-ESMO-ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease
Ann Oncol, 35 (3), 248-266
DOI 10.1016/j.annonc.2023.11.015, PubMed 38307807
Novel drug resistance mechanisms and drug targets in BRAF-mutated peritoneal metastasis from colorectal cancer
J Transl Med, 22 (1), 646
DOI 10.1186/s12967-024-05467-2, PubMed 38982444
Aligned or misaligned: Are public funding models for speech-language pathology reflecting recommended evidence? An exploratory survey of Australian speech-language pathologists
Health Policy Open, 6, 100117
DOI 10.1016/j.hpopen.2024.100117, PubMed 38510780
Evolutionary mode and timing of dissemination of high-grade serous carcinomas
JCI Insight, 9 (3)
DOI 10.1172/jci.insight.170423, PubMed 38175731
Publications 2023
External multicentre validation of pseudomyxoma peritonei PSOGI-Ki67 classification
Eur J Surg Oncol, 49 (8), 1481-1488
DOI 10.1016/j.ejso.2023.03.206, PubMed 36935222
Claudin-10 is a new candidate prognostic marker in metastatic high-grade serous carcinoma
Virchows Arch, 482 (6), 975-982
DOI 10.1007/s00428-023-03541-6, PubMed 37067588
Lymphovascular invasion and p16 expression are independent prognostic factors in stage I vulvar squamous cell carcinoma
Virchows Arch, 484 (6), 951-963
DOI 10.1007/s00428-023-03670-y, PubMed 37843640
Cancer Stem Cell Markers Are Differentially Expressed in Malignant Ovarian Germ Cell Tumors
Int J Gynecol Pathol, 42 (6), 613-619
DOI 10.1097/PGP.0000000000000947, PubMed 37186896
Occludin is overexpressed in tubo-ovarian high-grade serous carcinoma compared to mesothelioma and is a marker of tumor progression and chemoresistance
Clin Exp Metastasis, 41 (1), 69-76
DOI 10.1007/s10585-023-10251-5, PubMed 38141113
Clinical significance of L1CAM expression in metastatic tubo-ovarian high-grade serous carcinoma
Gynecol Oncol, 176, 76-81
DOI 10.1016/j.ygyno.2023.07.004, PubMed 37478615
Molecular characteristics of low-grade serous carcinoma in effusions
Cytopathology, 34 (2), 99-105
DOI 10.1111/cyt.13207, PubMed 36609991
Molecular features for timely cancer diagnosis and treatment - tumors of the ovary, fallopian tube and endometrium
Virchows Arch, 484 (2), 339-351
DOI 10.1007/s00428-023-03710-7, PubMed 38099957
Genetic Pathways in Peritoneal Mesothelioma Tumorigenesis
Cancer Genomics Proteomics, 20 (4), 363-374
DOI 10.21873/cgp.20388, PubMed 37400148
Endometrial Pipelle Biopsy Computer-Aided Diagnosis: A Feasibility Study
Mod Pathol, 37 (2), 100417
DOI 10.1016/j.modpat.2023.100417, PubMed 38154654
Publications 2022
Endometrial Carcinoma: Molecular Cytogenetics and Transcriptomic Profile
Cancers (Basel), 14 (14)
DOI 10.3390/cancers14143536, PubMed 35884597
Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions
Cytopathology, 33 (4), 479-492
DOI 10.1111/cyt.13126, PubMed 35398934
Comparison of the Idylla™ MSI assay with the Promega™ MSI Analysis System and immunohistochemistry on formalin-fixed paraffin-embedded tissue of endometrial carcinoma: results from an international, multicenter study
Virchows Arch, 480 (5), 1031-1039
DOI 10.1007/s00428-022-03291-x, PubMed 35124717
Data Set for the Reporting of Ovarian, Fallopian Tube and Primary Peritoneal Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR)
Int J Gynecol Pathol, 41 (Suppl 1), S119-S142
DOI 10.1097/PGP.0000000000000908, PubMed 36305537
Humanized Ovarian Cancer Patient-Derived Xenografts for Improved Preclinical Evaluation of Immunotherapies
Cancers (Basel), 14 (13)
DOI 10.3390/cancers14133092, PubMed 35804867
Exosome Secretion and Epithelial-Mesenchymal Transition in Ovarian Cancer Are Regulated by Phospholipase D
Int J Mol Sci, 23 (21)
DOI 10.3390/ijms232113286, PubMed 36362078
A Novel Cryptic t(2;3)(p21;q25) Translocation Fuses the WWTR1 and PRKCE Genes in Uterine Leiomyoma With 3q- as the Sole Visible Chromosome Abnormality
Cancer Genomics Proteomics, 19 (5), 636-646
DOI 10.21873/cgp.20348, PubMed 35985686
Fusion of the HMGA2 and BNC2 Genes in Uterine Leiomyoma With t(9;12)(p22;q14)
In Vivo, 36 (6), 2654-2661
DOI 10.21873/invivo.13000, PubMed 36309352
Integrating digital pathology with transcriptomic and epigenomic tools for predicting metastatic uterine tumor aggressiveness
Front Cell Dev Biol, 10, 1052098
DOI 10.3389/fcell.2022.1052098, PubMed 36467415
Serine metabolism remodeling after platinum-based chemotherapy identifies vulnerabilities in a subgroup of resistant ovarian cancers
Nat Commun, 13 (1), 4578
DOI 10.1038/s41467-022-32272-6, PubMed 35931688
Publications 2021
Anti-Angiogenic Treatment in Pseudomyxoma Peritonei-Still a Strong Preclinical Rationale
Cancers (Basel), 13 (11)
DOI 10.3390/cancers13112819, PubMed 34198773
Primary uterine ectomesenchymoma harboring a DICER1 mutation: case report with molecular analysis
Virchows Arch, 479 (2), 419-424
DOI 10.1007/s00428-021-03057-x, PubMed 33595736
Update on Sentinel Lymph Node Biopsy in Surgical Staging of Endometrial Carcinoma
J Clin Med, 10 (14)
DOI 10.3390/jcm10143094, PubMed 34300260
Peptide vaccine targeting mutated GNAS: a potential novel treatment for pseudomyxoma peritonei
J Immunother Cancer, 9 (10)
DOI 10.1136/jitc-2021-003109, PubMed 34711663
Comparison of Five Near-Infrared Fluorescent Folate Conjugates in an Ovarian Cancer Model
Mol Imaging Biol, 25 (1), 144-155
DOI 10.1007/s11307-021-01685-y, PubMed 34888759
Splice-Variant Knock-Out of TGFβ Receptors Perturbates the Proteome of Ovarian Carcinoma Cells
Int J Mol Sci, 22 (23)
DOI 10.3390/ijms222312647, PubMed 34884451
Community health and human-animal contacts on the edges of Bwindi Impenetrable National Park, Uganda
PLoS One, 16 (11), e0254467
DOI 10.1371/journal.pone.0254467, PubMed 34818325
Repurposing 18F-FMISO as a PET tracer for translational imaging of nitroreductase-based gene directed enzyme prodrug therapy
Theranostics, 11 (12), 6044-6057
DOI 10.7150/thno.55092, PubMed 33897898
Characterizing the Invasive Tumor Front of Aggressive Uterine Adenocarcinoma and Leiomyosarcoma
Front Cell Dev Biol, 9, 670185
DOI 10.3389/fcell.2021.670185, PubMed 34150764
Publications 2020
Intraperitoneal chemotherapy following neoadjuvant chemotherapy and optimal interval tumor reductive surgery for advanced ovarian cancer
Gynecol Oncol, 156 (3), 530-534
DOI 10.1016/j.ygyno.2019.12.016, PubMed 31937450
Role of the Exosome Secretion Machinery in Ovarian Carcinoma: In Vitro and In Vivo Models
J. Oncol., 2020, 4291827
DOI 10.1155/2020/4291827
Swallowing difficulties caused by a voice prosthesis in a laryngectomee
Eur Ann Otorhinolaryngol Head Neck Dis, 137 (5), 411-413
DOI 10.1016/j.anorl.2019.12.014, PubMed 32448709
Mutation analysis and genomic imbalances of cells found in effusion fluids from patients with ovarian cancer
Oncol Lett, 20 (3), 2273-2279
DOI 10.3892/ol.2020.11782, PubMed 32782545
Expression of Wnt pathway molecules is associated with disease outcome in metastatic high-grade serous carcinoma
Virchows Arch, 477 (2), 249-258
DOI 10.1007/s00428-019-02737-z, PubMed 31900634
Molecular testing on serous effusions
Diagn Cytopathol, 49 (5), 640-646
DOI 10.1002/dc.24392, PubMed 32023012
Expression of palladin is associated with disease progression in metastatic high-grade serous carcinoma
Cytopathology, 31 (6), 572-578
DOI 10.1111/cyt.12895, PubMed 32741023
The phosphatase PTPN1/PTP1B is a candidate marker of better chemotherapy response in metastatic high-grade serous carcinoma
Cytopathology, 32 (2), 161-168
DOI 10.1111/cyt.12921, PubMed 33025675
Expression of the cancer stem cell marker SSEA1 is associated with poor survival in metastatic high-grade serous carcinoma
Virchows Arch, 477 (5), 677-685
DOI 10.1007/s00428-020-02850-4, PubMed 32472195
The clinical, morphological, and genetic heterogeneity of endometrial stromal sarcoma
Virchows Arch, 476 (4), 489-490
DOI 10.1007/s00428-020-02762-3, PubMed 31993772
Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma
Virchows Arch, 477 (6), 857-864
DOI 10.1007/s00428-020-02842-4, PubMed 32533344
The Biological Role of the Long Non-coding RNA LINK-A in Ovarian Carcinoma
Anticancer Res, 40 (12), 6677-6684
DOI 10.21873/anticanres.14691, PubMed 33288561
The Biological and Clinical Role of the Long Non-Coding RNA LOC642852 in Ovarian Carcinoma
Int J Mol Sci, 21 (15)
DOI 10.3390/ijms21155237, PubMed 32718068
CD24-targeted intraoperative fluorescence image-guided surgery leads to improved cytoreduction of ovarian cancer in a preclinical orthotopic surgical model
EBioMedicine, 56, 102783
DOI 10.1016/j.ebiom.2020.102783, PubMed 32454402
Pulmonary Metastasectomy in Colorectal Cancer: updated analysis of 93 randomized patients - control survival is much better than previously assumed
Colorectal Dis, 22 (10), 1314-1324
DOI 10.1111/codi.15113, PubMed 32388895
Spatial and temporal changes in follicle distribution in the human ovarian cortex
Reprod Biomed Online, 42 (2), 375-383
DOI 10.1016/j.rbmo.2020.10.013, PubMed 33309389
Fifteen Years’ Experience with Vulvar Verrucous Carcinoma at a Single Norwegian Academic Cancer Center
Journal of Gynecology and Women Healthcare, 2 (2), 1-4
PublikaID 489
Inhibition of the MYC-Regulated Glutaminase Metabolic Axis Is an Effective Synthetic Lethal Approach for Treating Chemoresistant Ovarian Cancers
Cancer Res, 80 (20), 4514-4526
DOI 10.1158/0008-5472.CAN-19-3971, PubMed 32859605
Publications 2019
Integrated Molecular Analysis of Undifferentiated Uterine Sarcomas Reveals Clinically Relevant Molecular Subtypes
Clin Cancer Res, 25 (7), 2155-2165
DOI 10.1158/1078-0432.CCR-18-2792, PubMed 30617134
Molecular characterization of carcinosarcomas arising in the uterus and ovaries
Oncotarget, 10 (38), 3614-3624
DOI 10.18632/oncotarget.26942, PubMed 31217897
MGMT promoter methylation is a rare epigenetic change in malignant effusions
Cytopathology, 31 (1), 12-15
DOI 10.1111/cyt.12782, PubMed 31808217
Biomarkers of drug resistance in ovarian cancer - an update
Expert Rev Mol Diagn, 19 (6), 469-476
DOI 10.1080/14737159.2019.1618187, PubMed 31075061
Results of multigene panel testing in familial cancer cases without genetic cause demonstrated by single gene testing
Sci Rep, 9 (1), 18555
DOI 10.1038/s41598-019-54517-z, PubMed 31811167
ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis
Eur J Surg Oncol, 47 (1), 134-138
DOI 10.1016/j.ejso.2019.04.014, PubMed 31036394
Imaging biomarkers of adiposity and sarcopenia as potential predictors for overall survival among patients with endometrial cancer treated with bevacizumab
Gynecol Oncol Rep, 30, 100502
DOI 10.1016/j.gore.2019.100502, PubMed 31720357
Efficacy and Animal Welfare Impacts of Novel Capture Methods for Two Species of Invasive Wild Mammals in New Zealand
Animals (Basel), 10 (1)
DOI 10.3390/ani10010044, PubMed 31878314
Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response
Cold Spring Harb Mol Case Stud, 5 (2)
DOI 10.1101/mcs.a003566, PubMed 30862609
High-grade Endometrial Carcinomas: Morphologic and Immunohistochemical Features, Diagnostic Challenges and Recommendations
Int J Gynecol Pathol, 38 Suppl 1 (Iss 1 Suppl 1), S40-S63
DOI 10.1097/PGP.0000000000000491, PubMed 30550483
Diverse Effects of Lysophosphatidic Acid Receptors on Ovarian Cancer Signaling Pathways
J Oncol, 2019, 7547469
DOI 10.1155/2019/7547469, PubMed 31636669
SOX2 and SOX9 are markers of clinically aggressive disease in metastatic high-grade serous carcinoma
Gynecol Oncol, 153 (3), 651-660
DOI 10.1016/j.ygyno.2019.03.099, PubMed 30904337
Papilloma of the Fallopian Tube: A Rare Gynecologic Neoplasm Harboring a BRAF (c.1799T>A) Mutation (V600E)
Int J Gynecol Pathol, 38 (5), 459-463
DOI 10.1097/PGP.0000000000000526, PubMed 29851866
Spleen tyrosine kinase activity regulates epidermal growth factor receptor signaling pathway in ovarian cancer
EBioMedicine, 47, 184-194
DOI 10.1016/j.ebiom.2019.08.055, PubMed 31492560
Publications 2018
Identification of novel cyclin gene fusion transcripts in endometrioid ovarian carcinomas
Int J Cancer, 143 (6), 1379-1387
DOI 10.1002/ijc.31418, PubMed 29633253
The microRNA miR-192/215 family is upregulated in mucinous ovarian carcinomas
Sci Rep, 8 (1), 11069
DOI 10.1038/s41598-018-29332-7, PubMed 30038317
Identification of an EPC2-PHF1 fusion transcript in low-grade endometrial stromal sarcoma
Oncotarget, 9 (27), 19203-19208
DOI 10.18632/oncotarget.24969, PubMed 29721194
Expression and clinical role of the dipeptidyl peptidases DPP8 and DPP9 in ovarian carcinoma
Virchows Arch, 474 (2), 177-185
DOI 10.1007/s00428-018-2487-x, PubMed 30467600
Circulating tumor cells and cell-free nucleic acids in patients with gynecological malignancies
Virchows Arch, 473 (4), 395-403
DOI 10.1007/s00428-018-2447-5, PubMed 30145616
Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma
Gynecol Oncol, 150 (1), 136-142
DOI 10.1016/j.ygyno.2018.05.007, PubMed 29804637
Expression of 14-3-3 sigma and eta proteins is unrelated to survival in metastatic high-grade serous carcinoma
APMIS, 126 (4), 309-313
DOI 10.1111/apm.12816, PubMed 29464778
The diagnostic role of BAP1 in serous effusions
Hum Pathol, 79, 122-126
DOI 10.1016/j.humpath.2018.05.012, PubMed 29802871
Expression and clinical role of long non-coding RNA in high-grade serous carcinoma
Gynecol Oncol, 148 (3), 559-566
DOI 10.1016/j.ygyno.2018.01.004, PubMed 29310950
Soluble AXL is ubiquitously present in malignant serous effusions
Gynecol Oncol, 152 (2), 408-415
DOI 10.1016/j.ygyno.2018.11.012, PubMed 30448261
White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk
Ann Intern Med, 168 (5), 326-334
DOI 10.7326/M17-0101, PubMed 29335712
Can the classification of low-grade endometrial stromal tumors still be improved?
Virchows Arch, 473 (6), 663-664
DOI 10.1007/s00428-018-2474-2, PubMed 30367239
Activity and clinical relevance of autotaxin and lysophosphatidic acid pathways in high-grade serous carcinoma
Virchows Arch, 473 (4), 463-470
DOI 10.1007/s00428-018-2418-x, PubMed 30032361
Clinical Outcome of Patients With High-Risk Endometrial Carcinoma After Treatment With Chemotherapy Only
Int J Gynecol Cancer, 28 (9), 1789-1795
DOI 10.1097/IGC.0000000000001356, PubMed 30365455
Publications 2017
Genomic imbalances are involved in miR-30c and let-7a deregulation in ovarian tumors: implications for HMGA2 expression
Oncotarget, 8 (13), 21554-21560
DOI 10.18632/oncotarget.15795, PubMed 28423547
MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer
Oncotarget, 8 (37), 61800-61809
DOI 10.18632/oncotarget.18694, PubMed 28977905
Recurrent fusion transcripts in squamous cell carcinomas of the vulva
Oncotarget, 8 (10), 16843-16850
DOI 10.18632/oncotarget.15167, PubMed 28186972
RNA-sequencing identifies novel GREB1-NCOA2 fusion gene in a uterine sarcoma with the chromosomal translocation t(2;8)(p25;q13)
Genes Chromosomes Cancer, 57 (4), 176-181
DOI 10.1002/gcc.22518, PubMed 29218853
Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma
Virchows Arch, 471 (3), 355-362
DOI 10.1007/s00428-017-2172-5, PubMed 28643014
Molecular characteristics of uterine sarcomas
Expert Rev Mol Diagn, 17 (5), 515-522
DOI 10.1080/14737159.2017.1311790, PubMed 28335657
The diagnostic role of PTEN and ARID1A in serous effusions
Virchows Arch, 472 (3), 425-432
DOI 10.1007/s00428-017-2273-1, PubMed 29170871
Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial
Ann Surg Oncol, 24 (7), 1916-1922
DOI 10.1245/s10434-017-5814-6, PubMed 28224367
TGFβ splicing and canonical pathway activation in high-grade serous carcinoma
Virchows Arch, 470 (6), 665-678
DOI 10.1007/s00428-017-2127-x, PubMed 28432432
Validation of a Mitotic Index Cutoff as a Prognostic Marker in Undifferentiated Uterine Sarcomas
Am J Surg Pathol, 41 (9), 1231-1237
DOI 10.1097/PAS.0000000000000894, PubMed 28622181
Phospholipase D messenger RNA expression and clinical role in high-grade serous carcinoma
Hum Pathol, 62, 115-121
DOI 10.1016/j.humpath.2016.12.023, PubMed 28087476
ZC3H7B-BCOR high-grade endometrial stromal sarcomas: a report of 17 cases of a newly defined entity
Mod Pathol, 31 (4), 674-684
DOI 10.1038/modpathol.2017.162, PubMed 29192652
A Selective Biomarker Panel Increases the Reproducibility and the Accuracy in Endometrial Biopsy Diagnosis
Int J Gynecol Pathol, 36 (4), 339-347
DOI 10.1097/PGP.0000000000000334, PubMed 28244894
Quality of life is significantly associated with survival in women with advanced epithelial ovarian cancer: An ancillary data analysis of the NRG Oncology/Gynecologic Oncology Group (GOG-0218) study
Gynecol Oncol, 147 (1), 98-103
DOI 10.1016/j.ygyno.2017.07.121, PubMed 28743369
European Society of Gynaecological Oncology (ESGO) Guidelines for Ovarian Cancer Surgery
Int J Gynecol Cancer, 27 (7), 1534-1542
DOI 10.1097/IGC.0000000000001041, PubMed 30814245
Involvement of DPP9 in gene fusions in serous ovarian carcinoma
BMC Cancer, 17 (1), 642
DOI 10.1186/s12885-017-3625-6, PubMed 28893231
Epithelial-mesenchymal transition markers in malignant ovarian germ cell tumors
APMIS, 125 (9), 781-786
DOI 10.1111/apm.12715, PubMed 28585395
Major postoperative complications after pancreatic resection for P-NETS are not associated to earlier recurrence
Eur J Surg Oncol, 43 (11), 2119-2128
DOI 10.1016/j.ejso.2017.07.012, PubMed 28821361
Publications 2016
Expressions of miR-30c and let-7a are inversely correlated with HMGA2 expression in squamous cell carcinoma of the vulva
Oncotarget, 7 (51), 85058-85062
DOI 10.18632/oncotarget.13187, PubMed 27835588
A novel truncated form of HMGA2 in tumors of the ovaries
Oncol Lett, 12 (2), 1559-1563
DOI 10.3892/ol.2016.4805, PubMed 27446471
TSAP6 is a novel candidate marker of poor survival in metastatic high-grade serous carcinoma
Hum Pathol, 60, 180-187
DOI 10.1016/j.humpath.2016.10.017, PubMed 27825812
Recently identified drug resistance biomarkers in ovarian cancer
Expert Rev Mol Diagn, 16 (5), 569-78
DOI 10.1586/14737159.2016.1156532, PubMed 26895188
Malignant Nonhematological Effusion Characterization by Flow Cytometry
Acta Cytol, 60 (4), 365-371
DOI 10.1159/000447687, PubMed 27532128
CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells
Hum Pathol, 58, 123-127
DOI 10.1016/j.humpath.2016.08.005, PubMed 27589896
Progesterone Receptor Expression Is an Independent Prognosticator in FIGO Stage I Uterine Leiomyosarcoma
Am J Clin Pathol, 145 (4), 449-58
DOI 10.1093/ajcp/aqw030, PubMed 27149024
BAG-1/SODD, HSP70, and HSP90 are potential prognostic markers of poor survival in node-negative breast carcinoma
Hum Pathol, 54, 64-73
DOI 10.1016/j.humpath.2016.02.023, PubMed 27038683
Ezrin Is Associated with Disease Progression in Ovarian Carcinoma
PLoS One, 11 (9), e0162502
DOI 10.1371/journal.pone.0162502, PubMed 27622508
Ovarian Cancer Chemoresistance Relies on the Stem Cell Reprogramming Factor PBX1
Cancer Res, 76 (21), 6351-6361
DOI 10.1158/0008-5472.CAN-16-0980, PubMed 27590741
Genomewide copy number analysis of Müllerian adenosarcoma identified chromosomal instability in the aggressive subgroup
Mod Pathol, 29 (9), 1070-82
DOI 10.1038/modpathol.2016.99, PubMed 27255164
REG4 Is Highly Expressed in Mucinous Ovarian Cancer: A Potential Novel Serum Biomarker
PLoS One, 11 (3), e0151590
DOI 10.1371/journal.pone.0151590, PubMed 26981633
Cytogenetic and molecular profile of endometrial stromal sarcoma
Genes Chromosomes Cancer, 55 (11), 834-46
DOI 10.1002/gcc.22380, PubMed 27219024
Pre-analytical issues in effusion cytology
Pleura Peritoneum, 1 (1), 45-56
DOI 10.1515/pp-2016-0001, PubMed 30911607
MiR-29a is a candidate biomarker of better survival in metastatic high-grade serous carcinoma
Hum Pathol, 54, 74-81
DOI 10.1016/j.humpath.2016.03.010, PubMed 27063471
European Society of Gynaecologic Oncology Quality Indicators for Advanced Ovarian Cancer Surgery
Int J Gynecol Cancer, 26 (7), 1354-63
DOI 10.1097/IGC.0000000000000767, PubMed 27648648
Uterine leiomyosarcoma and endometrial stromal sarcoma have unique miRNA signatures
Gynecol Oncol, 140 (3), 512-7
DOI 10.1016/j.ygyno.2016.01.001, PubMed 26768834
Bilateral ovarian carcinomas differ in the expression of metastasis-related genes
Oncol Lett, 13 (1), 184-190
DOI 10.3892/ol.2016.5384, PubMed 28123539
L1CAM as a prognostic marker in stage I endometrial cancer: a validation study
BMC Cancer, 16, 596
DOI 10.1186/s12885-016-2631-4, PubMed 27488577
Novel Mad2-targeting miR-493-3p controls mitotic fidelity and cancer cells' sensitivity to paclitaxel
Oncotarget, 7 (11), 12267-85
DOI 10.18632/oncotarget.7860, PubMed 26943585
Reproducibility of measurement of myometrial invasion in endometrial carcinoma
Virchows Arch, 470 (1), 63-68
DOI 10.1007/s00428-016-2035-5, PubMed 27787595
Publications 2015
HMGA2 expression pattern and TERT mutations in tumors of the vulva
Oncol Rep, 33 (6), 2675-80
DOI 10.3892/or.2015.3882, PubMed 25823555
Intra-Gene DNA Methylation Variability Is a Clinically Independent Prognostic Marker in Women's Cancers
PLoS One, 10 (12), e0143178
DOI 10.1371/journal.pone.0143178, PubMed 26629914
Cost-effectiveness of noninvasive liver fibrosis tests for treatment decisions in patients with chronic hepatitis B in the UK: systematic review and economic evaluation
J Viral Hepat, 23 (2), 139-49
DOI 10.1111/jvh.12469, PubMed 26444996
Prognostic factors in malignant pleural mesothelioma
Hum Pathol, 46 (6), 789-804
DOI 10.1016/j.humpath.2015.02.006, PubMed 25824607
HUR mRNA expression in ovarian high-grade serous carcinoma effusions is associated with poor survival
Hum Pathol, 48, 95-101
DOI 10.1016/j.humpath.2015.09.027, PubMed 26640230
MMP-7 is a highly specific negative marker for benign and malignant mesothelial cells in serous effusions
Hum Pathol, 47 (1), 104-8
DOI 10.1016/j.humpath.2015.08.020, PubMed 26520416
Guidelines for cytopathologic diagnosis of epithelioid and mixed type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
Cytojournal, 12, 26
DOI 10.4103/1742-6413.170726, PubMed 26681974
Guidelines for the Cytopathologic Diagnosis of Epithelioid and Mixed-Type Malignant Mesothelioma: a secondary publication
Cytopathology, 26 (3), 142-56
DOI 10.1111/cyt.12250, PubMed 26052757
Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma: Complementary Statement from the International Mesothelioma Interest Group, Also Endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
Diagn Cytopathol, 43 (7), 563-76
DOI 10.1002/dc.23271, PubMed 26100969
Guidelines for the cytopathologic diagnosis of epithelioid and mixed-type malignant mesothelioma. Complementary statement from the International Mesothelioma Interest Group, also endorsed by the International Academy of Cytology and the Papanicolaou Society of Cytopathology
Acta Cytol, 59 (1), 2-16
DOI 10.1159/000377697, PubMed 25824655
Editorial: Advances in Epithelial Ovarian Cancer: Model Systems, Microenvironmental Influences, Therapy, and Origins
Front Oncol, 5, 205
DOI 10.3389/fonc.2015.00205, PubMed 26442217
Hsp70 (HSPA1) Lysine Methylation Status as a Potential Prognostic Factor in Metastatic High-Grade Serous Carcinoma
PLoS One, 10 (10), e0140168
DOI 10.1371/journal.pone.0140168, PubMed 26448330
MicroRNAs in Ovarian Cancer
Hum Pathol, 46 (9), 1245-56
DOI 10.1016/j.humpath.2015.06.013, PubMed 26216350
Protein expression of BIRC5, TK1, and TOP2A in malignant peripheral nerve sheath tumours--A prognostic test after surgical resection
Mol Oncol, 9 (6), 1129-39
DOI 10.1016/j.molonc.2015.02.005, PubMed 25769404
Liver resection rate following downsizing chemotherapy with cetuximab in metastatic colorectal cancer: UK retrospective observational study
Eur J Surg Oncol, 41 (4), 499-505
DOI 10.1016/j.ejso.2015.01.032, PubMed 25703078
Data set for reporting of ovary, fallopian tube and primary peritoneal carcinoma: recommendations from the International Collaboration on Cancer Reporting (ICCR)
Mod Pathol, 28 (8), 1101-22
DOI 10.1038/modpathol.2015.77, PubMed 26089092
Expression and clinical role of chemoresponse-associated genes in ovarian serous carcinoma
Gynecol Oncol, 139 (1), 30-9
DOI 10.1016/j.ygyno.2015.07.107, PubMed 26232338
CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma
Mol Cancer, 14, 44
DOI 10.1186/s12943-015-0317-1, PubMed 25889687
Developing regional nutrition team training across the North-East of England: reporting on the first nutrition team course run by the Northern Nutrition Network
Clin Nutr ESPEN, 10 (5), e194
DOI 10.1016/j.clnesp.2015.03.041, PubMed 28531510
HOTAIR and its surrogate DNA methylation signature indicate carboplatin resistance in ovarian cancer
Genome Med, 7, 108
DOI 10.1186/s13073-015-0233-4, PubMed 26497652
Inhibition of Spleen Tyrosine Kinase Potentiates Paclitaxel-Induced Cytotoxicity in Ovarian Cancer Cells by Stabilizing Microtubules
Cancer Cell, 28 (1), 82-96
DOI 10.1016/j.ccell.2015.05.009, PubMed 26096845
Publications 2014
The clinical role of epithelial-mesenchymal transition and stem cell markers in advanced-stage ovarian serous carcinoma effusions
Hum Pathol, 46 (1), 1-8
DOI 10.1016/j.humpath.2014.10.004, PubMed 25455994
BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma
Virchows Arch, 464 (6), 701-7
DOI 10.1007/s00428-014-1577-7, PubMed 24756216
VICKZ2 protein expression in ovarian serous carcinoma effusions is associated with poor survival
Hum Pathol, 45 (7), 1520-8
DOI 10.1016/j.humpath.2014.03.005, PubMed 24814803
Ovarian cancer: diagnostic, biological and prognostic aspects
Womens Health (Lond), 10 (5), 519-33
DOI 10.2217/whe.14.37, PubMed 25335543
The clinical and diagnostic role of microRNAs in ovarian carcinoma
Gynecol Oncol, 133 (3), 640-6
DOI 10.1016/j.ygyno.2014.03.575, PubMed 24713546
The role of the tumor stroma in ovarian cancer
Front Oncol, 4, 104
DOI 10.3389/fonc.2014.00104, PubMed 24860785
Validity and reliability of the new Canadian Nutrition Screening Tool in the 'real-world' hospital setting
Eur J Clin Nutr, 69 (5), 558-64
DOI 10.1038/ejcn.2014.270, PubMed 25514899
Mnk2 alternative splicing modulates the p38-MAPK pathway and impacts Ras-induced transformation
Cell Rep, 7 (2), 501-513
DOI 10.1016/j.celrep.2014.03.041, PubMed 24726367
Prognostic biomarkers in endometrial and ovarian carcinoma
Virchows Arch, 464 (3), 315-31
DOI 10.1007/s00428-013-1509-y, PubMed 24504546
MEAF6/PHF1 is a recurrent gene fusion in endometrial stromal sarcoma
Cancer Lett, 347 (1), 75-8
DOI 10.1016/j.canlet.2014.01.030, PubMed 24530230
Genomic profile of ovarian carcinomas
BMC Cancer, 14, 315
DOI 10.1186/1471-2407-14-315, PubMed 24886194
Low frequency of ESRRA-C11orf20 fusion gene in ovarian carcinomas
PLoS Biol, 12 (2), e1001784
DOI 10.1371/journal.pbio.1001784, PubMed 24504521
Novel TNS3-MAP3K3 and ZFPM2-ELF5 fusion genes identified by RNA sequencing in multicystic mesothelioma with t(7;17)(p12;q23) and t(8;11)(q23;p13)
Cancer Lett, 357 (2), 502-9
DOI 10.1016/j.canlet.2014.12.002, PubMed 25484136
Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions
Gynecol Oncol, 135 (1), 118-24
DOI 10.1016/j.ygyno.2014.07.102, PubMed 25093290
Chromosome 19 rearrangements in ovarian carcinomas: zinc finger genes are particularly targeted
Genes Chromosomes Cancer, 53 (7), 558-67
DOI 10.1002/gcc.22166, PubMed 24634323
APOA1 mRNA expression in ovarian serous carcinoma effusions is a marker of longer survival
Am J Clin Pathol, 142 (1), 51-7
DOI 10.1309/AJCPD8NBSHXRXQL7, PubMed 24926085
Exosome-derived miRNAs and ovarian carcinoma progression
Carcinogenesis, 35 (9), 2113-20
DOI 10.1093/carcin/bgu130, PubMed 24925027
Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker
BMC Cancer, 14, 80
DOI 10.1186/1471-2407-14-80, PubMed 24512620
Publications 2013
Translational predictive biomarker analysis of the phase 1b sorafenib and bevacizumab study expansion cohort
Mol Cell Proteomics, 12 (6), 1621-31
DOI 10.1074/mcp.M112.026427, PubMed 23449826
Hepatocyte nuclear factor-1β is not a specific marker of clear cell carcinoma in serous effusions
Cancer Cytopathol, 122 (2), 153-8
DOI 10.1002/cncy.21353, PubMed 24115587
Gene expression signatures of primary and metastatic uterine leiomyosarcoma
Hum Pathol, 45 (4), 691-700
DOI 10.1016/j.humpath.2013.11.003, PubMed 24485798
Defining a prognostic marker panel for patients with ovarian serous carcinoma effusion
Hum Pathol, 44 (11), 2449-60
DOI 10.1016/j.humpath.2013.06.003, PubMed 24011953
Histotype-genotype correlation in 36 high-grade endometrial carcinomas
Am J Surg Pathol, 37 (9), 1421-32
DOI 10.1097/PAS.0b013e31828c63ed, PubMed 24076778
Providing quality nutrition care in acute care hospitals: perspectives of nutrition care personnel
J Hum Nutr Diet, 27 (2), 192-202
DOI 10.1111/jhn.12170, PubMed 24147893
Genomic aberration patterns and expression profiles of squamous cell carcinomas of the vulva
Genes Chromosomes Cancer, 52 (6), 551-63
DOI 10.1002/gcc.22053, PubMed 23404381
Fusion of the ZC3H7B and BCOR genes in endometrial stromal sarcomas carrying an X;22-translocation
Genes Chromosomes Cancer, 52 (7), 610-8
DOI 10.1002/gcc.22057, PubMed 23580382
RNA sequencing identifies fusion of the EWSR1 and YY1 genes in mesothelioma with t(14;22)(q32;q12)
Genes Chromosomes Cancer, 52 (8), 733-40
DOI 10.1002/gcc.22068, PubMed 23630070
HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival
Gynecol Oncol, 129 (2), 358-63
DOI 10.1016/j.ygyno.2013.02.021, PubMed 23438671
Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer
EMBO Mol Med, 5 (7), 1051-66
DOI 10.1002/emmm.201201823, PubMed 23666744
Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases
Hum Pathol, 44 (12), 2677-83
DOI 10.1016/j.humpath.2013.07.009, PubMed 24060004
Proton magnetic resonance metabolomic characterization of ovarian serous carcinoma effusions: chemotherapy-related effects and comparison with malignant mesothelioma and breast carcinoma
Hum Pathol, 44 (9), 1859-66
DOI 10.1016/j.humpath.2013.02.009, PubMed 23656974
Publications 2012
S6K1 alternative splicing modulates its oncogenic activity and regulates mTORC1
Cell Rep, 3 (1), 103-15
DOI 10.1016/j.celrep.2012.11.020, PubMed 23273915
PRAME (preferentially expressed antigen of melanoma) is a novel marker for differentiating serous carcinoma from malignant mesothelioma
Am J Clin Pathol, 137 (2), 240-7
DOI 10.1309/AJCPGA95KVSAUDMF, PubMed 22261449
Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma
Virchows Arch, 460 (2), 193-202
DOI 10.1007/s00428-011-1191-x, PubMed 22249560
Gene expression signatures differentiate uterine endometrial stromal sarcoma from leiomyosarcoma
Gynecol Oncol, 128 (2), 349-55
DOI 10.1016/j.ygyno.2012.11.021, PubMed 23178314
The diagnostic and research applications of flow cytometry in cytopathology
Diagn Cytopathol, 40 (6), 525-35
DOI 10.1002/dc.22809, PubMed 22619127
Migfilin, α-parvin and β-parvin are differentially expressed in ovarian serous carcinoma effusions, primary tumors and solid metastases
Gynecol Oncol, 128 (2), 364-70
DOI 10.1016/j.ygyno.2012.10.015, PubMed 23099104
Epithelial-mesenchymal transition in ovarian carcinoma
Front Oncol, 2, 33
DOI 10.3389/fonc.2012.00033, PubMed 22655269
Prognostic significance of residual tumor in patients with epithelial ovarian carcinoma stage IV in a 20 year perspective
Acta Obstet Gynecol Scand, 91 (3), 308-17
DOI 10.1111/j.1600-0412.2011.01316.x, PubMed 22050605
Multidrug resistance-linked gene signature predicts overall survival of patients with primary ovarian serous carcinoma
Clin Cancer Res, 18 (11), 3197-206
DOI 10.1158/1078-0432.CCR-12-0056, PubMed 22492981
HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases
Virchows Arch, 460 (5), 505-13
DOI 10.1007/s00428-012-1228-9, PubMed 22476403
Predicting platinum resistance in primary advanced ovarian cancer patients with an in vitro resistance index
Cancer Chemother Pharmacol, 69 (5), 1307-14
DOI 10.1007/s00280-012-1835-9, PubMed 22302409
MGST1 expression in serous ovarian carcinoma differs at various anatomic sites, but is unrelated to chemoresistance or survival
Gynecol Oncol, 126 (3), 460-5
DOI 10.1016/j.ygyno.2012.05.029, PubMed 22652154
Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance
Hum Pathol, 44 (5), 777-85
DOI 10.1016/j.humpath.2012.08.002, PubMed 23114921
IKK-ε coordinates invasion and metastasis of ovarian cancer
Cancer Res, 72 (21), 5494-504
DOI 10.1158/0008-5472.CAN-11-3993, PubMed 22942254
Ezrin and BCAR1/p130Cas mediate breast cancer growth as 3-D spheroids
Clin Exp Metastasis, 29 (6), 527-40
DOI 10.1007/s10585-012-9468-2, PubMed 22476538
Novel fusion of MYST/Esa1-associated factor 6 and PHF1 in endometrial stromal sarcoma
PLoS One, 7 (6), e39354
DOI 10.1371/journal.pone.0039354, PubMed 22761769
DNA ploidy may be a prognostic marker in stage I and II serous adenocarcinoma of the endometrium
Virchows Arch, 461 (3), 291-8
DOI 10.1007/s00428-012-1275-2, PubMed 22824999
Alternatively spliced lysyl oxidase-like 4 isoforms have a pro-metastatic role in cancer
Clin Exp Metastasis, 30 (1), 103-17
DOI 10.1007/s10585-012-9514-0, PubMed 22806361
AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma
Virchows Arch, 462 (2), 163-73
DOI 10.1007/s00428-012-1347-3, PubMed 23242172
Neoadjuvant chemotherapy, interval debulking surgery or primary surgery in ovarian carcinoma FIGO stage IV?
Eur J Cancer, 48 (14), 2146-54
DOI 10.1016/j.ejca.2012.01.031, PubMed 22382201
Borderline ovarian tumours
Best Pract Res Clin Obstet Gynaecol, 26 (3), 325-36
DOI 10.1016/j.bpobgyn.2011.12.006, PubMed 22321906
Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma
Hum Pathol, 43 (11), 2062-9
DOI 10.1016/j.humpath.2012.02.016, PubMed 22647351
Hyaluronan synthase and hyaluronidase expression in serous ovarian carcinoma is related to anatomic site and chemotherapy exposure
Int J Mol Sci, 13 (10), 12925-38
DOI 10.3390/ijms131012925, PubMed 23202930
Publications 2011
Sustained induction of neuronal addition to the adult rat neostriatum by AAV4-delivered noggin and BDNF
Gene Ther, 19 (5), 483-93
DOI 10.1038/gt.2011.114, PubMed 21918547
Nucleoside transporters are widely expressed in ovarian carcinoma effusions
Cancer Chemother Pharmacol, 69 (2), 467-75
DOI 10.1007/s00280-011-1716-7, PubMed 21822668
SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions
Hum Pathol, 43 (5), 669-74
DOI 10.1016/j.humpath.2011.06.003, PubMed 21855113
Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status
Tumour Biol, 32 (3), 589-96
DOI 10.1007/s13277-011-0157-6, PubMed 21350924
Expression of the Ets transcription factor EHF in serous ovarian carcinoma effusions is a marker of poor survival
Hum Pathol, 43 (4), 496-505
DOI 10.1016/j.humpath.2011.05.023, PubMed 21855111
Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome
Hum Pathol, 42 (7), 991-7
DOI 10.1016/j.humpath.2010.10.013, PubMed 21315424
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from breast carcinoma in effusions
J Cell Mol Med, 15 (3), 535-44
DOI 10.1111/j.1582-4934.2010.01023.x, PubMed 20132413
Gene expression signatures differentiate adenocarcinoma of lung and breast origin in effusions
Hum Pathol, 43 (5), 684-94
DOI 10.1016/j.humpath.2011.06.015, PubMed 21937081
Flow cytometric measurement of cellular FLICE-inhibitory protein (c-FLIP) in ovarian carcinoma effusions
Cytopathology, 22 (6), 373-82
DOI 10.1111/j.1365-2303.2011.00929.x, PubMed 22032542
Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions
Hum Pathol, 43 (4), 529-35
DOI 10.1016/j.humpath.2011.05.022, PubMed 21864883
Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance
Proc Natl Acad Sci U S A, 108 (46), 18708-13
DOI 10.1073/pnas.1111840108, PubMed 22068913
Clinical relevance of multidrug resistance gene expression in ovarian serous carcinoma effusions
Mol Pharm, 8 (6), 2080-8
DOI 10.1021/mp200240a, PubMed 21761824
Class III β-tubulin expression in advanced-stage serous ovarian carcinoma effusions is associated with poor survival and primary chemoresistance
Hum Pathol, 42 (7), 1019-26
DOI 10.1016/j.humpath.2010.10.025, PubMed 21315408
Paracrine SLPI secretion upregulates MMP-9 transcription and secretion in ovarian cancer cells
Gynecol Oncol, 122 (3), 656-62
DOI 10.1016/j.ygyno.2011.04.052, PubMed 21676452
Adhesion molecule protein signature in ovarian cancer effusions is prognostic of patient outcome
Cancer, 118 (6), 1543-53
DOI 10.1002/cncr.26449, PubMed 22009736
Expression and clinical role of protein of regenerating liver (PRL) phosphatases in ovarian carcinoma
Int J Mol Sci, 12 (2), 1133-45
DOI 10.3390/ijms12021133, PubMed 21541048
Recommendations to replace peripheral venous catheters every 72-96 hours: is a single reference enough?
J Hosp Infect, 79 (2), 172-3
DOI 10.1016/j.jhin.2011.06.005, PubMed 21802173
Immunocytochemistry in Europe: results of the European Federation of Cytology Societies (EFCS) inquiry
Cytopathology, 22 (4), 238-42
DOI 10.1111/j.1365-2303.2011.00885.x, PubMed 21771093
miRNA profiling along tumour progression in ovarian carcinoma
J Cell Mol Med, 15 (7), 1593-602
DOI 10.1111/j.1582-4934.2010.01148.x, PubMed 20716115
Do random estimations of vitamin D3 and parathyroid hormone reflect the 24-h profile in the critically ill?
Intensive Care Med, 38 (1), 177-9
DOI 10.1007/s00134-011-2415-x, PubMed 22113816
PINCH-2 expression in cancers involving serosal effusions using quantitative PCR
Cytopathology, 22 (1), 22-9
DOI 10.1111/j.1365-2303.2010.00757.x, PubMed 20500520
Publications 2010
Nuclear factor kappaB transcription factors are coexpressed and convey a poor outcome in ovarian cancer
Cancer, 116 (13), 3276-84
DOI 10.1002/cncr.25190, PubMed 20564628
Expression and clinical role of growth differentiation factor-15 in ovarian carcinoma effusions
Int J Gynecol Cancer, 20 (9), 1448-55
DOI 10.1111/IGC.0b013e3181f7d6be, PubMed 21336029
Mammalian target of rapamycin is a biomarker of poor survival in metastatic serous ovarian carcinoma
Hum Pathol, 41 (6), 794-804
DOI 10.1016/j.humpath.2009.09.017, PubMed 20153512
The diagnostic and molecular characteristics of malignant mesothelioma and ovarian/peritoneal serous carcinoma
Cytopathology, 22 (1), 5-21
DOI 10.1111/j.1365-2303.2010.00829.x, PubMed 21114695
New determinates of disease progression and outcome in metastatic ovarian carcinoma
Histol Histopathol, 25 (12), 1591-609
DOI 10.14670/HH-25.1591, PubMed 20886439
CD105 (Endoglin) expression in breast carcinoma effusions is a marker of poor survival
Breast, 19 (6), 493-8
DOI 10.1016/j.breast.2010.05.013, PubMed 21078485
Measurement of apoptosis in cytological specimens by flow cytometry: comparison of Annexin V, caspase cleavage and dUTP incorporation assays
Cytopathology, 22 (6), 365-72
DOI 10.1111/j.1365-2303.2010.00811.x, PubMed 21054589
Mesenchymal-to-epithelial transition determinants as characteristics of ovarian carcinoma effusions
Clin Exp Metastasis, 27 (3), 161-72
DOI 10.1007/s10585-010-9315-2, PubMed 20213325
Exploring the peritoneal surface malignancy phenotype--a pilot immunohistochemical study of human pseudomyxoma peritonei and derived animal models
Hum Pathol, 41 (8), 1109-19
DOI 10.1016/j.humpath.2009.12.013, PubMed 20338618
Activation of NF-kappaB signaling by inhibitor of NF-kappaB kinase beta increases aggressiveness of ovarian cancer
Cancer Res, 70 (10), 4005-14
DOI 10.1158/0008-5472.CAN-09-3912, PubMed 20424119
Oncoproteomic analysis reveals co-upregulation of RELA and STAT5 in carboplatin resistant ovarian carcinoma
PLoS One, 5 (6), e11198
DOI 10.1371/journal.pone.0011198, PubMed 20585448
Genomic aberrations in borderline ovarian tumors
J Transl Med, 8, 21
DOI 10.1186/1479-5876-8-21, PubMed 20184781
Biological effects induced by insulin-like growth factor binding protein 3 (IGFBP-3) in malignant melanoma
Int J Cancer, 126 (2), 350-61
DOI 10.1002/ijc.24727, PubMed 19588500
Notch3 overexpression is related to the recurrence of ovarian cancer and confers resistance to carboplatin
Am J Pathol, 177 (3), 1087-94
DOI 10.2353/ajpath.2010.100316, PubMed 20671266
DNA ploidy heterogeneity in endometrial carcinoma: comparison between curettage and hysterectomy specimens
Int J Gynecol Pathol, 29 (6), 572-8
DOI 10.1097/PGP.0b013e3181e2e8ee, PubMed 20881853
Distinct DNA methylation profiles in ovarian serous neoplasms and their implications in ovarian carcinogenesis
Am J Obstet Gynecol, 203 (6), 584.e1-22
DOI 10.1016/j.ajog.2010.08.003, PubMed 20965493
Growth differentiation factor-15 as a prognostic biomarker in ovarian cancer
Gynecol Oncol, 118 (3), 237-43
DOI 10.1016/j.ygyno.2010.05.032, PubMed 20576287
Expression of Fatty Acid Synthase Depends on NAC1 and Is Associated with Recurrent Ovarian Serous Carcinomas
J Oncol, 2010, 285191
DOI 10.1155/2010/285191, PubMed 20508725
Molecular genetic markers in female reproductive cancers
J Oncol, 2010, 307460
DOI 10.1155/2010/307460, PubMed 21541207
Matched Gene Selection and Committee Classifier for Molecular Classification of Heterogeneous Diseases
J. Mach. Learn. Res., 11, 2141-2167
Netrin-4 is upregulated in breast carcinoma effusions compared to corresponding solid tumors
Diagn Cytopathol, 39 (8), 562-6
DOI 10.1002/dc.21424, PubMed 20730893
Publications 2009
Expression of the peroxisome proliferator-activated receptors-alpha, -beta, and -gamma in ovarian carcinoma effusions is associated with poor chemoresponse and shorter survival
Hum Pathol, 40 (5), 705-13
DOI 10.1016/j.humpath.2008.09.019, PubMed 19157507
Evaluation of cell surface expression of phosphatidylserine in ovarian carcinoma effusions using the annexin-V/7-AAD assay: clinical relevance and comparison with other apoptosis parameters
Am J Clin Pathol, 132 (5), 756-62
DOI 10.1309/AJCPAVFA8J3KHPRS, PubMed 19846818
Expression and clinical role of antiapoptotic proteins of the bag, heat shock, and Bcl-2 families in effusions, primary tumors, and solid metastases in ovarian carcinoma
Int J Gynecol Pathol, 28 (3), 211-21
DOI 10.1097/PGP.0b013e31818b0f5e, PubMed 19620938
Cell survival and apoptosis-related molecules in cancer cells in effusions: a comprehensive review
Diagn Cytopathol, 37 (8), 613-24
DOI 10.1002/dc.21095, PubMed 19418469
Cleaved caspase-3 and nuclear factor-kappaB p65 are prognostic factors in metastatic serous ovarian carcinoma
Hum Pathol, 40 (6), 795-806
DOI 10.1016/j.humpath.2008.10.019, PubMed 19157506
Breast carcinoma cells in primary tumors and effusions have different gene array profiles
J Oncol, 2010, 969084
DOI 10.1155/2010/969084, PubMed 19680458
Different expression and clinical role of S100A4 in serous ovarian carcinoma at different anatomic sites
Tumour Biol, 30 (1), 15-25
DOI 10.1159/000199447, PubMed 19194111
Gross genomic alterations differ between serous borderline tumors and serous adenocarcinomas--an image cytometric DNA ploidy analysis of 307 cases with histogenetic implications
Virchows Arch, 454 (6), 677-83
DOI 10.1007/s00428-009-0778-y, PubMed 19421773
Large scale genomic instability as an additive prognostic marker in early prostate cancer
Cell Oncol, 31 (4), 251-9
DOI 10.3233/CLO-2009-0463, PubMed 19633362
Pathogenesis of ovarian cancer: clues from selected overexpressed genes
Future Oncol, 5 (10), 1641-57
DOI 10.2217/fon.09.126, PubMed 20001801
Diagnostic and prognostic role of the insulin growth factor pathway members insulin-like growth factor-II and insulin-like growth factor binding protein-3 in serous effusions
Hum Pathol, 40 (4), 527-37
DOI 10.1016/j.humpath.2008.10.003, PubMed 19121847
Diagnosis and treatment of borderline ovarian neoplasms "the state of the art"
Eur J Gynaecol Oncol, 30 (5), 471-82
PubMed 19899396
The anti-apoptotic activity of BAG3 is restricted by caspases and the proteasome
PLoS One, 4 (4), e5136
DOI 10.1371/journal.pone.0005136, PubMed 19352495
Expression of the folate receptor genes FOLR1 and FOLR3 differentiates ovarian carcinoma from breast carcinoma and malignant mesothelioma in serous effusions
Hum Pathol, 40 (10), 1453-60
DOI 10.1016/j.humpath.2009.02.013, PubMed 19454358
Tenascin-X is a novel diagnostic marker of malignant mesothelioma
Am J Surg Pathol, 33 (11), 1673-82
DOI 10.1097/PAS.0b013e3181b6bde3, PubMed 19738457
Publications 2008
Jagged-1 and Notch3 juxtacrine loop regulates ovarian tumor growth and adhesion
Cancer Res, 68 (14), 5716-23
DOI 10.1158/0008-5472.CAN-08-0001, PubMed 18632624
MicroRNA expression and identification of putative miRNA targets in ovarian cancer
PLoS One, 3 (6), e2436
DOI 10.1371/journal.pone.0002436, PubMed 18560586
New diagnostic and molecular characteristics of malignant mesothelioma
Ultrastruct Pathol, 32 (6), 227-40
DOI 10.1080/01913120802454298, PubMed 19117264
The chemokine receptor CXCR4 is more frequently expressed in breast compared to other metastatic adenocarcinomas in effusions
Breast J, 14 (5), 476-82
DOI 10.1111/j.1524-4741.2008.00625.x, PubMed 18657145
Different clinical roles for p21-activated kinase-1 in primary and recurrent ovarian carcinoma
Hum Pathol, 39 (11), 1630-6
DOI 10.1016/j.humpath.2008.03.009, PubMed 18656238
Expression of the chromatin remodeling factor Rsf-1 is down-regulated in breast carcinoma effusions
Hum Pathol, 39 (4), 616-22
DOI 10.1016/j.humpath.2007.09.008, PubMed 18289639
Methods for simultaneous measurement of apoptosis and cell surface phenotype of epithelial cells in effusions by flow cytometry
Nat Protoc, 3 (6), 955-64
DOI 10.1038/nprot.2008.77, PubMed 18546596
Death receptor expression is associated with poor response to chemotherapy and shorter survival in metastatic ovarian carcinoma
Cancer, 112 (1), 84-93
DOI 10.1002/cncr.23140, PubMed 17985388
Claudin upregulation in ovarian carcinoma effusions is associated with poor survival
Hum Pathol, 39 (5), 747-57
DOI 10.1016/j.humpath.2007.10.002, PubMed 18439941
Ovarian carcinoma cells in effusions show increased S-phase fraction compared to corresponding primary tumors
Diagn Cytopathol, 36 (9), 637-44
DOI 10.1002/dc.20879, PubMed 18677760
Small interfering RNA molecules targeting endothelin-converting enzyme-1 inhibit endothelin-1 synthesis and the invasive phenotype of ovarian carcinoma cells
Cancer Res, 68 (22), 9265-73
DOI 10.1158/0008-5472.CAN-08-2093, PubMed 19010899
Lysyl oxidase-like 4 is alternatively spliced in an anatomic site-specific manner in tumors involving the serosal cavities
Virchows Arch, 454 (1), 71-9
DOI 10.1007/s00428-008-0694-6, PubMed 19015874
The fatty acid binding protein 7 (FABP7) is involved in proliferation and invasion of melanoma cells
BMC Cancer, 8, 276
DOI 10.1186/1471-2407-8-276, PubMed 18826602
Circulating calprotectin in ovarian carcinomas and borderline tumors of the ovary
Am J Obstet Gynecol, 198 (4), 418.e1-7
DOI 10.1016/j.ajog.2007.10.792, PubMed 18241816
Assessment of endoglin and calprotectin as potential biomarkers in ovarian carcinoma and borderline tumors of the ovary
Am J Obstet Gynecol, 199 (5), 533.e1-8
DOI 10.1016/j.ajog.2008.04.004, PubMed 18533117
Publications 2007
BAG-4/SODD and associated antiapoptotic proteins are linked to aggressiveness of epithelial ovarian cancer
Clin Cancer Res, 13 (22 Pt 1), 6585-92
DOI 10.1158/1078-0432.CCR-07-0327, PubMed 18006758
Anatomic site-related expression of cancer-associated molecules in ovarian carcinoma
Curr Cancer Drug Targets, 7 (1), 109-20
DOI 10.2174/156800907780006904, PubMed 17305482
Biological characteristics of cancers involving the serosal cavities
Crit Rev Oncog, 13 (3), 189-227
DOI 10.1615/critrevoncog.v13.i3.10, PubMed 18298385
Expression of cancer-associated molecules in malignant mesothelioma
Biomark Insights, 2, 173-84
PubMed 19662202
MUC4 is upregulated in ovarian carcinoma effusions and differentiates carcinoma cells from mesothelial cells
Diagn Cytopathol, 35 (12), 756-60
DOI 10.1002/dc.20771, PubMed 18008338
Expression and clinical role of the bric-a-brac tramtrack broad complex/poxvirus and zinc protein NAC-1 in ovarian carcinoma effusions
Hum Pathol, 38 (7), 1030-1036
DOI 10.1016/j.humpath.2006.12.009, PubMed 17391728
Chemokine receptors are infrequently expressed in malignant and benign mesothelial cells
Am J Clin Pathol, 127 (5), 752-9
DOI 10.1309/LN2075V7C8K31CH8, PubMed 17439834
Flow cytometric immunophenotyping of cancer cells in effusion specimens: diagnostic and research applications
Diagn Cytopathol, 35 (9), 568-78
DOI 10.1002/dc.20707, PubMed 17703449
Expression and clinical role of DJ-1, a negative regulator of PTEN, in ovarian carcinoma
Hum Pathol, 39 (1), 87-95
DOI 10.1016/j.humpath.2007.05.014, PubMed 17949781
Low-molecular weight forms of cyclin E differentiate ovarian carcinoma from cells of mesothelial origin and are associated with poor survival in ovarian carcinoma
Cancer, 110 (6), 1264-71
DOI 10.1002/cncr.22918, PubMed 17647260
Kallikrein 4 is expressed in malignant mesothelioma--further evidence for the histogenetic link between mesothelial and epithelial cells
Diagn Cytopathol, 35 (2), 80-4
DOI 10.1002/dc.20588, PubMed 17230566
Flow cytometric immunphenotyping of epithelial cancer cells in effusions--technical considerations and pitfalls
Cytometry B Clin Cytom, 72 (5), 332-43
DOI 10.1002/cyto.b.20172, PubMed 17226863
The carbon footprint of laparoscopic surgery: should we offset?
Surg Endosc, 22 (2), 573
DOI 10.1007/s00464-007-9722-x, PubMed 18095020
Survivin, a member of the inhibitors of apoptosis family, is down-regulated in breast carcinoma effusions
Am J Clin Pathol, 128 (3), 389-97
DOI 10.1309/E899BG1282M5D505, PubMed 17709312
Nuclear expression of survivin is associated with improved survival in metastatic ovarian carcinoma
Cancer, 109 (2), 228-38
DOI 10.1002/cncr.22426, PubMed 17167759
The diagnostic role of claudins in serous effusions
Am J Clin Pathol, 127 (6), 928-37
DOI 10.1309/V025QRN3R9CJGNPX, PubMed 17509990
Expression of inhibitor-of-apoptosis protein family members in malignant mesothelioma
Hum Pathol, 38 (7), 986-994
DOI 10.1016/j.humpath.2006.12.013, PubMed 17350081
Measurement of cyclin E genomic copy number and strand length in cell-free DNA distinguish malignant versus benign effusions
Clin Cancer Res, 13 (19), 5805-9
DOI 10.1158/1078-0432.CCR-07-0853, PubMed 17908972
Molecular based treatment of oral cancer (Retraction of vol 39, pg 749, 2003)
Oral Oncol., 43 (4), 421
DOI 10.1016/j.oraloncology.2007.01.004
Publications 2006
D2-40 is not a specific marker for cells of mesothelial origin in serous effusions
Am J Surg Pathol, 30 (7), 878-82
DOI 10.1097/01.pas.0000208280.29291.34, PubMed 16819331
Fine-needle aspiration cytology of the thyroid gland: comparative analysis of experience at three hospitals
Diagn Cytopathol, 34 (2), 97-100
DOI 10.1002/dc.20384, PubMed 16514672
Proteomic analysis of malignant ovarian cancer effusions as a tool for biologic and prognostic profiling
Clin Cancer Res, 12 (3 Pt 1), 791-9
DOI 10.1158/1078-0432.CCR-05-2516, PubMed 16467090
The mitogen-activated protein kinases (MAPK) p38 and JNK are markers of tumor progression in breast carcinoma
Gynecol Oncol, 102 (3), 453-61
DOI 10.1016/j.ygyno.2006.01.034, PubMed 16494928
The biological differences between ovarian serous carcinoma and diffuse peritoneal malignant mesothelioma
Semin Diagn Pathol, 23 (1), 35-43
DOI 10.1053/j.semdp.2006.06.003, PubMed 17044194
Heparanase expression correlates with poor survival in metastatic ovarian carcinoma
Gynecol Oncol, 104 (2), 311-9
DOI 10.1016/j.ygyno.2006.08.045, PubMed 17030350
Expression of the chromatin remodeling factor Rsf-1 is upregulated in ovarian carcinoma effusions and predicts poor survival
Gynecol Oncol, 103 (3), 814-9
DOI 10.1016/j.ygyno.2006.05.042, PubMed 16844205
Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma
Clin Cancer Res, 12 (20 Pt 1), 5944-50
DOI 10.1158/1078-0432.CCR-06-1059, PubMed 17062665
NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma
Am J Clin Pathol, 125 (3), 451-8
DOI 10.1309/15B66DQMFYYM78CJ, PubMed 16613351
Expression of E-cadherin transcriptional regulators in ovarian carcinoma
Virchows Arch, 449 (5), 520-8
DOI 10.1007/s00428-006-0274-6, PubMed 17024425
The clinical role of phospholipase A2 isoforms in advanced-stage ovarian carcinoma
Gynecol Oncol, 103 (3), 831-40
DOI 10.1016/j.ygyno.2006.06.042, PubMed 16919315
Doxorubicin levels in the serum and ascites of patients with ovarian cancer
Eur J Surg Oncol, 33 (2), 213-5
DOI 10.1016/j.ejso.2006.11.006, PubMed 17174514
Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma
Mod Pathol, 19 (11), 1446-55
DOI 10.1038/modpathol.3800662, PubMed 16951673
Expression of HLA-G in malignant mesothelioma and clinically aggressive breast carcinoma
Virchows Arch, 449 (1), 31-9
DOI 10.1007/s00428-005-0144-7, PubMed 16541284
Homozygous deletion of MKK4 in ovarian serous carcinoma
Cancer Biol Ther, 5 (6), 630-4
DOI 10.4161/cbt.5.6.2675, PubMed 16627982
A BTB/POZ protein, NAC-1, is related to tumor recurrence and is essential for tumor growth and survival
Proc Natl Acad Sci U S A, 103 (49), 18739-44
DOI 10.1073/pnas.0604083103, PubMed 17130457
Notch3 gene amplification in ovarian cancer
Cancer Res, 66 (12), 6312-8
DOI 10.1158/0008-5472.CAN-05-3610, PubMed 16778208
The p75 neurotrophin receptor is widely expressed in conventional papillary thyroid carcinoma
Hum Pathol, 37 (5), 562-8
DOI 10.1016/j.humpath.2005.12.016, PubMed 16647954
Cadherin expression in ovarian carcinoma and malignant mesothelioma cell effusions
Acta Cytol, 50 (6), 603-7
DOI 10.1159/000326027, PubMed 17152269
Expression of Snail, Slug and Sip1 in malignant mesothelioma effusions is associated with matrix metalloproteinase, but not with cadherin expression
Lung Cancer, 54 (3), 309-17
DOI 10.1016/j.lungcan.2006.08.010, PubMed 16996643
The activated nerve growth factor receptor p-TrkA is selectively expressed in advanced-stage ovarian carcinoma
Hum Pathol, 38 (1), 140-6
DOI 10.1016/j.humpath.2006.06.027, PubMed 16996570
Publications 2005
Identification and characterization of membralin, a novel tumor-associated gene, in ovarian carcinoma
Biochim Biophys Acta, 1730 (2), 96-102
DOI 10.1016/j.bbaexp.2005.06.008, PubMed 16084606
Apolipoprotein E is required for cell proliferation and survival in ovarian cancer
Cancer Res, 65 (1), 331-7
PubMed 15665311
Primary ovarian angiosarcoma presenting as malignant cells in ascites: case report and review of the literature
Diagn Cytopathol, 32 (5), 307-9
DOI 10.1002/dc.20245, PubMed 15830366
HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma
Gynecol Oncol, 96 (1), 42-7
DOI 10.1016/j.ygyno.2004.09.049, PubMed 15589578
Site-related expression of metastasis-associated and signaling molecules in malignant mesothelioma--a new model for the study of tumor biology and disease progression
Lung Cancer, 49 Suppl 1, S89-93
DOI 10.1016/j.lungcan.2005.03.026, PubMed 15950809
Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions
Am J Clin Pathol, 123 (3), 360-8
DOI 10.1309/PTBB-5BPC-KX8K-9V69, PubMed 15716231
Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma
Cancer, 103 (8), 1631-43
DOI 10.1002/cncr.20946, PubMed 15742334
Laminin-induced signaling in tumor cells
Cancer Lett, 223 (1), 1-10
DOI 10.1016/j.canlet.2004.08.030, PubMed 15890231
Angiogenic molecule expression is downregulated in effusions from breast cancer patients
Breast Cancer Res Treat, 94 (1), 71-80
DOI 10.1007/s10549-005-7328-3, PubMed 16142438
Differential expression of the 67 kilodalton laminin receptor in epithelioid malignant mesothelioma and carcinomas that spread to serosal cavities
Diagn Cytopathol, 33 (5), 332-7
DOI 10.1002/dc.20296, PubMed 16240397
Variation in gene expression patterns in effusions and primary tumors from serous ovarian cancer patients
Mol Cancer, 4, 26
DOI 10.1186/1476-4598-4-26, PubMed 16042759
Amplification of a chromatin remodeling gene, Rsf-1/HBXAP, in ovarian carcinoma
Proc Natl Acad Sci U S A, 102 (39), 14004-9
DOI 10.1073/pnas.0504195102, PubMed 16172393
Quantitative analysis of integrin expression in effusions using flow cytometric immunophenotyping
Diagn Cytopathol, 33 (5), 325-31
DOI 10.1002/dc.20282, PubMed 16240402
Expression of activated Akt and PTEN in malignant melanomas: relationship with clinical outcome
Am J Clin Pathol, 124 (4), 528-36
DOI 10.1309/YT58WWMTA6YR1PRV, PubMed 16146807
Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma
Cancer, 103 (11), 2313-9
DOI 10.1002/cncr.21031, PubMed 15844177
Risk markers of oral cancer in clinically normal mucosa as an aid in smoking cessation counseling
J Clin Oncol, 23 (9), 1927-33 (Retracted)
DOI 10.1200/JCO.2005.03.172, PubMed 15774785
Mitogen-activated protein kinase expression and activation does not differentiate benign from malignant mesothelial cells
Cancer, 103 (11), 2427-33
DOI 10.1002/cncr.21014, PubMed 15830375
The AP-2gamma transcription factor is upregulated in advanced-stage ovarian carcinoma
Gynecol Oncol, 100 (3), 462-8
DOI 10.1016/j.ygyno.2005.09.022, PubMed 16216317
Publications 2004
Malignant effusions: from diagnosis to biology
Diagn Cytopathol, 31 (4), 246-54
DOI 10.1002/dc.20133, PubMed 15452897
Granulin-epithelin precursor is a novel prognostic marker in epithelial ovarian carcinoma
Cancer, 100 (10), 2139-47
DOI 10.1002/cncr.20219, PubMed 15139056
The clinical role of the PEA3 transcription factor in ovarian and breast carcinoma in effusions
Clin Exp Metastasis, 21 (3), 191-9
DOI 10.1023/b:clin.0000037703.37275.35, PubMed 15387369
Altered expression of metastasis-associated and regulatory molecules in effusions from breast cancer patients: a novel model for tumor progression
Clin Cancer Res, 10 (21), 7335-46
DOI 10.1158/1078-0432.CCR-04-0183, PubMed 15534110
Altered expression and activation of the nerve growth factor receptors TrkA and p75 provide the first evidence of tumor progression to effusion in breast carcinoma
Breast Cancer Res Treat, 83 (2), 119-28
DOI 10.1023/B:BREA.0000010704.17479.8a, PubMed 14997042
Expression of the nerve growth factor receptors TrkA and p75 in malignant mesothelioma
Lung Cancer, 44 (2), 159-65
DOI 10.1016/j.lungcan.2003.11.014, PubMed 15084380
Malignant mesothelioma
Ultrastruct Pathol, 28 (4), 179-80
DOI 10.1080/01913120490518051, PubMed 15693629
Heparanase and basic fibroblast growth factor are co-expressed in malignant mesothelioma
Clin Exp Metastasis, 21 (5), 469-76
DOI 10.1007/s10585-004-3150-2, PubMed 15672872
Expression of activated TrkA protein in melanocytic tumors: relationship to cell proliferation and clinical outcome
Am J Clin Pathol, 122 (3), 412-20
DOI 10.1309/CHFH-EYAT-44WW-P7J3, PubMed 15362372
The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma
Gynecol Oncol, 93 (2), 517-23
DOI 10.1016/j.ygyno.2004.03.009, PubMed 15099972
Laminin-induced signaling in tumor cells: the role of the M(r) 67,000 laminin receptor
Cancer Res, 64 (10), 3572-9
DOI 10.1158/0008-5472.CAN-03-3424, PubMed 15150114
Proteomics and ovarian cancer: implications for diagnosis and treatment: a critical review of the recent literature
Curr Opin Oncol, 16 (5), 478-84
DOI 10.1097/00001622-200409000-00012, PubMed 15314519
The role of flow cytometric immunophenotyping in improving the diagnostic accuracy in referred fine-needle aspiration specimens
Diagn Cytopathol, 31 (3), 159-63
DOI 10.1002/dc.20108, PubMed 15349984
Proteomics in cancer
Ann Oncol, 15 Suppl 4, iv167-71
DOI 10.1093/annonc/mdh922, PubMed 15477302
Kallikrein 4 is associated with paclitaxel resistance in ovarian cancer
Gynecol Oncol, 94 (1), 80-5
DOI 10.1016/j.ygyno.2004.03.044, PubMed 15262123
Publications 2003
Fine-needle aspiration cytology vs. core biopsy in the diagnosis of breast lesions
Diagn Cytopathol, 29 (6), 344-8
DOI 10.1002/dc.10372, PubMed 14648793
Matrix metalloproteinases (MMP), EMMPRIN (extracellular matrix metalloproteinase inducer) and mitogen-activated protein kinases (MAPK): co-expression in metastatic serous ovarian carcinoma
Clin Exp Metastasis, 20 (7), 621-31
DOI 10.1023/a:1027347932543, PubMed 14669793
EMMPRIN (extracellular matrix metalloproteinase inducer) is a novel marker of poor outcome in serous ovarian carcinoma
Clin Exp Metastasis, 20 (2), 161-9
DOI 10.1023/a:1022696012668, PubMed 12705637
PEA3 is the second Ets family transcription factor involved in tumor progression in ovarian carcinoma
Clin Cancer Res, 9 (4), 1412-9
PubMed 12684413
Coordinated expression of integrin subunits, matrix metalloproteinases (MMP), angiogenic genes and Ets transcription factors in advanced-stage ovarian carcinoma: a possible activation pathway?
Cancer Metastasis Rev, 22 (1), 103-15
DOI 10.1023/a:1022272204045, PubMed 12716042
AlphaV- and beta1-integrin subunits are commonly expressed in malignant effusions from ovarian carcinoma patients
Gynecol Oncol, 90 (2), 248-57
DOI 10.1016/s0090-8258(03)00321-4, PubMed 12893184
Expression and activation of the nerve growth factor receptor TrkA in serous ovarian carcinoma
Clin Cancer Res, 9 (6), 2248-59
PubMed 12796393
Effusion cytology in ovarian cancer: new molecular methods as aids to diagnosis and prognosis
Clin Lab Med, 23 (3), 729-54, viii
DOI 10.1016/s0272-2712(03)00058-1, PubMed 14560537
Mitogen-activated protein kinases (MAPK) as predictors of clinical outcome in serous ovarian carcinoma in effusions
Gynecol Oncol, 91 (1), 160-72
DOI 10.1016/s0090-8258(03)00434-7, PubMed 14529677
Expression of the 67 kDa laminin receptor and the alpha6 integrin subunit in serous ovarian carcinoma
Clin Exp Metastasis, 20 (7), 599-609
DOI 10.1023/a:1027340208536, PubMed 14669791
Molecular based treatment of oral cancer
Oral Oncol, 39 (8), 749-58 (Retracted)
DOI 10.1016/s1368-8375(03)00098-8, PubMed 13679198
Publications 2002
Detection of malignant epithelial cells in effusions using flow cytometric immunophenotyping: an analysis of 92 cases
Am J Clin Pathol, 118 (1), 85-92
DOI 10.1309/M877-QABM-D9GB-FJAX, PubMed 12109861
Caveolin-1 expression in ovarian carcinoma is MDR1 independent
Am J Clin Pathol, 117 (2), 225-34
DOI 10.1309/u40r-1bn4-6kj3-bdg3, PubMed 11863219
The prognostic value of metalloproteinases and angiogenic factors in ovarian carcinoma
Mol Cell Endocrinol, 187 (1-2), 39-45
DOI 10.1016/s0303-7207(01)00709-2, PubMed 11988310
Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions
Clin Exp Metastasis, 19 (2), 135-44
DOI 10.1023/a:1014582911680, PubMed 11964077
The biological role and regulation of matrix metalloproteinases (MMP) in cancer
Arkh Patol, 64 (3), 47-53
PubMed 15338725
Adenomatous polyposis coli (APC) protein expression in primary and metastatic serous ovarian carcinoma
Int J Surg Pathol, 10 (3), 175-80
DOI 10.1177/106689690201000302, PubMed 12232570
Dissociated expression of Bcl-2 and Ki-67 in endometrial lesions: diagnostic and histogenetic implications
Int J Gynecol Pathol, 21 (2), 155-60
DOI 10.1097/00004347-200204000-00008, PubMed 11917225
Fine-needle aspiration cytology of lobular carcinoma in situ
Diagn Cytopathol, 27 (1), 22-6
DOI 10.1002/dc.10128, PubMed 12112810
Cystic change in metastatic lymph nodes: a common diagnostic pitfall in fine-needle aspiration cytology
Diagn Cytopathol, 27 (6), 387-92
DOI 10.1002/dc.10201, PubMed 12451573
Publications 2001
Reduced expression of plakoglobin correlates with adverse outcome in patients with neuroblastoma
Am J Pathol, 159 (1), 43-9
DOI 10.1016/S0002-9440(10)61671-9, PubMed 11438452
Infertility treatment after conservative management of borderline ovarian tumors
Cancer, 92 (2), 320-5
DOI 10.1002/1097-0142(20010715)92:2<320::aid-cncr1325>3.0.co;2-g, PubMed 11466685
Ovarian carcinoma and serous effusions. Changing views regarding tumor progression and review of current literature
Anal Cell Pathol, 23 (3-4), 107-28
DOI 10.1155/2001/418547, PubMed 12082292
Ovarian carcinoma and serous effusions: a patho-biological study
Department of Pathology, The Norwegian Radium Hospital, University of Oslo, Oslo, 1 b. (flere pag.)
BIBSYS 011165863, ISBN 82-7633-155-6
Expression of membrane-type 1, 2, and 3 matrix metalloproteinases messenger RNA in ovarian carcinoma cells in serous effusions
Am J Clin Pathol, 115 (4), 517-24
DOI 10.1309/B1YX-L8DB-TGY1-7905, PubMed 11293899
Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients
Clin Cancer Res, 7 (11), 3457-64
PubMed 11705863
Caveolin-1 expression in advanced-stage ovarian carcinoma--a clinicopathologic study
Gynecol Oncol, 81 (2), 166-71
DOI 10.1006/gyno.2001.6156, PubMed 11330944
The role of desmin and N-cadherin in effusion cytology: a comparative study using established markers of mesothelial and epithelial cells
Am J Surg Pathol, 25 (11), 1405-12
DOI 10.1097/00000478-200111000-00008, PubMed 11684957
Ovarian carcinoma cells in serous effusions show altered MMP-2 and TIMP-2 mRNA levels
Eur J Cancer, 37 (16), 2040-9
DOI 10.1016/s0959-8049(01)00235-0, PubMed 11597382
Ets-1 messenger RNA expression is a novel marker of poor survival in ovarian carcinoma
Clin Cancer Res, 7 (3), 551-7
PubMed 11297247
Expression of cell cycle proteins in ovarian carcinoma cells in serous effusions-biological and prognostic implications
Gynecol Oncol, 83 (2), 249-56
DOI 10.1006/gyno.2001.6388, PubMed 11606079
Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome
Am J Surg Pathol, 25 (12), 1493-500
DOI 10.1097/00000478-200112000-00004, PubMed 11717538
Alphav integrin expression is a novel marker of poor prognosis in advanced-stage ovarian carcinoma
Clin Cancer Res, 7 (12), 4073-9
PubMed 11751504
Topoisomerase II immunostaining as a prognostic marker for survival in ovarian cancer
Gynecol Oncol, 82 (1), 99-104
DOI 10.1006/gyno.2001.6208, PubMed 11426969
Detection of monocyte/macrophage cell populations in effusions: a comparative study using flow cytometric immunophenotyping and immunocytochemistry
Diagn Cytopathol, 25 (4), 214-9
DOI 10.1002/dc.2041, PubMed 11599103
Publications 2000
Expression of CD44 in effusions of patients diagnosed with serous ovarian carcinoma--diagnostic and prognostic implications
Clin Exp Metastasis, 18 (2), 197-202
DOI 10.1023/a:1006711320107, PubMed 11235996
Differential expression of CD44s and CD44v3-10 in adenocarcinoma cells and reactive mesothelial cells in effusions
Virchows Arch, 436 (4), 330-5
DOI 10.1007/s004280050455, PubMed 10834535
Traumatic intratumoral hemorrhage as the presenting symptom of a spinal neurinoma. Case report
J Neurosurg, 93 (2 Suppl), 327-9
DOI 10.3171/spi.2000.93.2.0327, PubMed 11012070
[Serous effusions]
Tidsskr Nor Laegeforen, 120 (3), 367-72
PubMed 10827531
E-cadherin and alpha-, beta-, and gamma-catenin protein expression is up-regulated in ovarian carcinoma cells in serous effusions
J Pathol, 192 (4), 460-9
DOI 10.1002/1096-9896(2000)9999:9999<::AID-PATH726>3.0.CO;2-M, PubMed 11113863
Carbohydrate antigen expression in primary tumors, metastatic lesions, and serous effusions from patients diagnosed with epithelial ovarian carcinoma: evidence of up-regulated Tn and Sialyl Tn antigen expression in effusions
Hum Pathol, 31 (9), 1081-7
DOI 10.1053/hupa.2000.9776, PubMed 11014575
Expression of angiogenesis-related genes in ovarian carcinoma--a clinicopathologic study
Clin Exp Metastasis, 18 (6), 501-7
DOI 10.1023/a:1011858225144, PubMed 11592307
Expression of topoisomerase II and Ki-67 in cervical carcinoma--clinicopathological study using immunohistochemistry
APMIS, 108 (3), 209-15
DOI 10.1034/j.1600-0463.2000.d01-46.x, PubMed 10752690
Expression of carbohydrate antigens in advanced-stage ovarian carcinomas and their metastases-A clinicopathologic study
Gynecol Oncol, 77 (1), 35-43
DOI 10.1006/gyno.1999.5708, PubMed 10739688
E-Cadherin complex protein expression and survival in ovarian carcinoma
Gynecol Oncol, 79 (3), 362-71
DOI 10.1006/gyno.2000.5964, PubMed 11104606
CA 125 measurement and ultrasonography in borderline tumors of the ovary
Am J Obstet Gynecol, 183 (3), 541-6
DOI 10.1067/mob.2000.105940, PubMed 10992171
Flow cytometric immunophenotyping of serous effusions and peritoneal washings: comparison with immunocytochemistry and morphological findings
J Clin Pathol, 53 (7), 513-7
DOI 10.1136/jcp.53.7.513, PubMed 10961174
The influence of cytomegalovirus viraemia on the outcome of recurrent hepatitis C after liver transplantation
Transplantation, 70 (10), 1454-8
DOI 10.1097/00007890-200011270-00010, PubMed 11118089
Publications 1999
From the ashes of experience: reflections on madness survival and growth
Whurr publishers, London, 192 s.
BIBSYS 040599426, ISBN 1-86156-120-2
High levels of MMP-2, MMP-9, MT1-MMP and TIMP-2 mRNA correlate with poor survival in ovarian carcinoma
Clin Exp Metastasis, 17 (10), 799-808
DOI 10.1023/a:1006723011835, PubMed 11089877
Macrophage infiltration and angiogenesis in cervical squamous cell carcinoma--clinicopathologic correlation
Acta Obstet Gynecol Scand, 78 (3), 240-4
PubMed 10078587
MMP-2 and TIMP-2 expression correlates with poor prognosis in cervical carcinoma--a clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
Gynecol Oncol, 73 (3), 372-82
DOI 10.1006/gyno.1999.5381, PubMed 10366463
Expression of matrix metalloproteinase-9 in squamous cell carcinoma of the uterine cervix-clinicopathologic study using immunohistochemistry and mRNA in situ hybridization
Gynecol Oncol, 72 (3), 380-6
DOI 10.1006/gyno.1998.5285, PubMed 10053110
Evaluation of lymphoid cell populations in cytology specimens using flow cytometry and polymerase chain reaction
Diagn Mol Pathol, 8 (4), 183-8
DOI 10.1097/00019606-199912000-00003, PubMed 10617274
Detection of cancer cells in effusions from patients diagnosed with gynaecological malignancies. Evaluation of five epithelial markers
Virchows Arch, 435 (1), 43-9
DOI 10.1007/s004280050393, PubMed 10431845
Expression of metalloproteinases endometrial stromal sarcoma: immunohistochemical study using image analysis
J Clin Pathol, 52 (3), 198-202
DOI 10.1136/jcp.52.3.198, PubMed 10450179
Systemic vasculitis with multiple aneurysms complicating systemic lupus erythematosus
J R Soc Med, 92 (12), 636-7
DOI 10.1177/014107689909201209, PubMed 10692887
Successful use of a covered nitinol self-expanding stent to seal a malignant fistula of the common bile duct
Clin Radiol, 54 (6), 410-2
DOI 10.1053/crad.1999.0050, PubMed 10406346
Publications 1998
Psychiatric nursing: ethical strife
Arnold, London, XVIII, 359 s.
BIBSYS 960847499, ISBN 0-340-62523-6
Expression of rasGTPase activating protein in basal cell carcinoma of the skin
Mod Pathol, 11 (3), 271-5
PubMed 9521474
Immunohistochemical analysis of rasGTPase activating protein (rasGAP) in prostate cancer
Pathol Res Pract, 194 (6), 399-404
DOI 10.1016/S0344-0338(98)80030-7, PubMed 9689648
CD44 expression in uterine cervical intraepithelial neoplasia and squamous cell carcinoma: an immunohistochemical study
Eur J Gynaecol Oncol, 19 (1), 46-9
PubMed 9476059
Expression of matrix proteins in uterine cervical neoplasia using immunohistochemistry
Eur J Obstet Gynecol Reprod Biol, 76 (1), 109-14
DOI 10.1016/s0301-2115(97)00161-9, PubMed 9481557
Ulex Europaeus lectin and anti-CD31 staining in squamous cell carcinoma of the uterine cervix: potential prognostic markers
Int J Gynecol Pathol, 17 (3), 205-10
DOI 10.1097/00004347-199807000-00003, PubMed 9656115
Expression of metalloproteinases and their inhibitors in adenocarcinoma of the uterine cervix
Int J Gynecol Pathol, 17 (4), 295-301
DOI 10.1097/00004347-199810000-00002, PubMed 9785129
Expression of extracellular matrix proteins in cervical squamous cell carcinoma--a clinicopathological study
J Clin Pathol, 51 (10), 781-5
DOI 10.1136/jcp.51.10.781, PubMed 10023343
Borderline tumors of the ovary: fertility treatment, conservative management, and pregnancy outcome
Cancer, 82 (1), 141-6
PubMed 9428490
Rates of Jewish ancestral mutations in BRCA1 and BRCA2 in borderline ovarian tumors
J Natl Cancer Inst, 90 (13), 995-1000
DOI 10.1093/jnci/90.13.995, PubMed 9665148
Publications 1997
Inflammatory response in cervical intraepithelial neoplasia and squamous cell carcinoma of the uterine cervix
Pathol Res Pract, 193 (7), 491-5
DOI 10.1016/s0344-0338(97)80102-1, PubMed 9342755
Angiogenesis in uterine cervical intraepithelial neoplasia and squamous cell carcinoma: an immunohistochemical study
Int J Gynecol Pathol, 16 (4), 335-8
DOI 10.1097/00004347-199710000-00007, PubMed 9421072
[Genetic defects in neurodegenerative diseases]
Harefuah, 132 (7), 481-5
PubMed 9153920
Chronic massive knee effusion in familial Mediterranean fever
Semin Arthritis Rheum, 27 (3), 169-72
DOI 10.1016/s0049-0172(97)80016-9, PubMed 9431588
Publications 1995
[Molecular biology of human papilloma virus infection of the female genital tract]
Harefuah, 129 (10), 417-20
PubMed 8647548